This enduring activity will focus on improving clinicians knowledge and competence in selecting among the available TROP2-directed ADCs and incorporating them into treatment strategies for patients with HR-positive, HER2-negative/low advanced or metastatic breast cancer. As a result of this educational activity, learners should be better able to: 1. Identify the role of TROP2-directed ADCs in the treatment of HR-positive, HER2-negative/low advanced or metastatic breast cancer; 2. Review the clinical profiles of TROP2-directed ADCs for patients with pretreated HR positive, HER2-negative/low advanced or metastatic breast cancer; and, 3. Apply guideline-concordant, evidence-based strategies to incorporate TROP2-directed ADCs into treatment plans for patients with pretreated HR-positive, HER2-negative/low advanced or metastatic breast cancer. Learners will have access to downloadable materials.
Credit & MOC Details
Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.
Credit types
MOC types
FDA REMS
Qualifies for MIPS
Target Specialties
Pricing
99% of listed courses are free
156 of 157 courses listed here are free.
Collected from the provider’s public pages
Specialties served/covered
- Allergy & Clinical Immunology
- Anatomic & Clinical Pathology
- Cardiovascular Disease
- Communication & Shared Decision-Making
- Critical Care Medicine
- Dermatology
- Diagnostic Radiology
- Endocrinology, Diabetes & Metabolism
- Family Medicine
- Gastroenterology
- Gastrointestinal Surgery
- General Internal Medicine
- General Pediatrics
- General Surgery
- Gynecologic Oncology
- Hematology
- Infectious Disease
- Interventional Cardiology
- Maternal-Fetal Medicine
- Medical Oncology
- Nephrology
- Neurocritical Care
- Neurology
- Neuromuscular Medicine
- Obstetrics & Gynecology
- Ophthalmology
- Pediatric Gastroenterology
- Pediatric Infectious Diseases
- Pulmonary Disease
- Rheumatology
- Sleep Medicine
- Surgical Oncology
- Transplant Hepatology
- Urological Oncology
- Urology
- Vascular Neurology
- Cardio-Vascular
- Cross-Specialty
- Emergency & Critical Care
- GI & Liver
- Infectious Disease
- Internal Medicine
- Medical Subspecialties
- Neurology
- Ob/Gyn
- Oncology & Hematology
- Pathology & Lab
- Pediatrics
- Primary care
- Radiology
- Surgery
- Urology
- No reviews yet. Be the first to share yours.
Pricing
Free
Reported to ACCME by the provider
- Microlearning
- Credit · Up to 0.5 credits
- Commercial Support
-
ReleasedNov 13, 2025
-
Last day to claim creditNov 13, 2026 4 weeks left
-
Answers in CME Inc. (AiCME) ADC-elerating Progress: Targeting TROP2 in Triple-Negative Breast Cancer to Improve Front-Line Care
-
Answers in CME Inc. (AiCME) Bridging Clinic and OR: A Dialogue on the Emerging Role of Neoadjuvant HER2-Directed ADCs in HER2+ Breast Cancer
-
Answers in CME Inc. (AiCME) What s Now and What s Next for ADCs in NSCLC? Integrating HER2- and TROP2-Targeted Therapies Into the Evolving Treatment Landscape
